| Literature DB >> 15207074 |
Karine Grenet1, Didier Guillemot, Vincent Jarlier, Brigitte Moreau, Stéphane Dubourdieu, Raymond Ruimy, Laurence Armand-Lefevre, Pierre Bau, Antoine Andremont.
Abstract
Drug resistance in fecal bacteria was high in Wayampis Amerindians who did not take antibacterial agents and were not hospitalized for 1 year. In the Wayampis Amerindians, an isolated traditional community in French Guyana, antibacterial use was 0.64 treatments per person per year. Hospitalization rate was 6.1% per year. Antibacterial drug-resistant bacteria can spread in persons who are not taking antibacterial agents.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15207074 PMCID: PMC3323165 DOI: 10.3201/eid1006.031015
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Antibacterial exposure in 388 Wayampi Amerindians from three villages in southern French Guyana during the year preceding the studya
| Antibacterial agents | Frequency of antibacterial exposure in (%) | ||||
|---|---|---|---|---|---|
| TS (n = 85) | YP (n = 55) | Z (n = 248) | Total (N = 388) | p valueb | |
| Aminopenicillins | 5.9 | 14.6 | 23.8 | 18.6 | 0.007 |
| Metronidazole | 16.5 | 30.9 | 32.3 | 28.6 | 0.15 |
| Macrolides | 8.2 | 1.8 | 11.3 | 9.3 | 0.2 |
| Other | 5.8 | 7.3 | 8.9 | 8.0 | 0.7 |
| Overall | 36.5 | 54.6 | 76.2 | 64.4 | 0.007 |
aFrequency of antibacterial exposure was calculated by dividing the number of all antibacterial courses during the year preceding the study by the number of persons in each village. bAnalysis of variance (ANOVA).
Prevalence of carriage of gram-negative bacteria resistant to various antibacterial agents in the predominant and the subdominant fecal flora of the 93 study participantsa
| Antibacterial agent | Predominant florab | Subdominant flora | ||||||
|---|---|---|---|---|---|---|---|---|
| Other (%) | Any (%) | Lactose positive (%) | Lactose negative (%) | Any (%) | ||||
| Ampicillin | 51 (55) | 19 (21) | 5 (5) | 2 (2) | 77 (83) | 89 (96) | 31 (33) | 93 (100) |
| Ceftazidime | 0 | 0 | 0 | 0 | 0 | 3c (4) | 11d (12) | 14 (15) |
| Nalidixic acid | 0 | 0 | 0 | 0 | 0 | 7e (8) | 0 | 7 (8) |
| Pefloxacine | 0 | 0 | 0 | 0 | 0 | ND | ND | ND |
| Streptomycin | 42 (45) | 2 (2) | 0 | 0 | 44 (47) | 83 (90) | 19 (21) | 86 (93) |
| Kanamycin | 5 (5) | 0 | 0 | 0 | 5 (5) | 45 (49) | 4 (5) | 47 (51) |
| Tetracycline | 59 (63) | 14 (15) | 0 | 2 (2) | 75 (81) | 86 (93) | 25 (27) | 86 (93) |
| Cotrimoxazole | 27 (29) | 0 | 0 | 0 | 27 (29) | ND | ND | ND |
| Chloramphenicol | 22 (24) | 0 | 0 | 0 | 22 (24) | 48 (52) | 27 (29) | 60 (67) |
aAccounting for 23.9% (93 of 388) of the global population of the villages studied and not significantly different from it for male/female ratio or age distribution. bBacteria with intermediate susceptibility were categorized as resistant. cExtended spectrum β-lactamase E. coli. dAcinetobacter baumanni: 9 (all with the same susceptibility pattern including susceptibility to ureidopenicillins, third-generation cephalosporins, aminoglycosides, and quinolones) and Ochrobactrum spp. (identified by 16s RNA genes sequencing): 2. eE. coli.